BVF Inc’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BVF Inc’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,614,662	Closed	-$1.97M	–	61
2024 Q2	$1.97M	Hold	3,614,662	–	–	0.06%	53
2024 Q1	$3.69M	Hold	3,614,662	–	–	0.1%	54
2023 Q4	$2.06M	Hold	3,614,662	–	–	0.05%	63
2023 Q3	$3.76M	Hold	3,614,662	–	–	0.1%	57
2023 Q2	$5.1M	Hold	3,614,662	–	–	0.14%	53
2023 Q1	$5.75M	Hold	3,614,662	–	–	0.21%	56
2022 Q4	$5.28M	Hold	3,614,662	–	–	0.22%	58
2022 Q3	$15.4M	Hold	3,614,662	–	–	0.64%	47
2022 Q2	$14M	Hold	3,614,662	–	–	0.68%	41
2022 Q1	$17.2M	Buy	3,614,662 +175,718	+5%	+$529K	0.69%	38
2021 Q4	$12.6M	Buy	3,438,944 +344,770	+11%	+$1.84M	0.46%	51
2021 Q3	$24.8M	Hold	3,094,174	–	–	0.97%	28
2021 Q2	$35.1M	Hold	3,094,174	–	–	1.32%	19
2021 Q1	$28.6M	Buy	3,094,174 +2,600,657	+527%	+$27.1M	1.07%	26
2020 Q4	$3.44M	Hold	493,517	–	–	0.14%	61
2020 Q3	$2.16M	Buy	493,517 +419,376	+566%	+$3.66M	0.12%	59
2020 Q2	$684K	Sell	74,141 -102,857	-58%	-$1.55M	0.04%	56
2020 Q1	$2.57M	Hold	176,998	–	–	0.24%	49
2019 Q4	$2.09M	Hold	176,998	–	–	0.16%	50
2019 Q3	$4.46M	Sell	176,998 -16,443	-9%	-$475K	0.47%	46
2019 Q2	$4.92M	Buy	193,441 +128,074	+196%	+$4.95M	0.54%	42
2019 Q1	$2.78M	Hold	65,367	–	–	0.31%	46
2018 Q4	$951K	Buy	65,367 +17,235	+36%	+$703K	0.12%	52
2018 Q3	$3.37M	Hold	48,132	–	–	0.3%	50
2018 Q2	$3.57M	Hold	48,132	–	–	0.35%	46
2018 Q1	$4.58M	Sell	48,132 -10,245	-18%	-$1.76M	0.46%	37
2017 Q4	$7.54M	Hold	58,377	–	–	0.91%	28
2017 Q3	$3.96M	Buy	58,377 +7,786	+15%	+$636K	0.5%	32
2017 Q2	$4.78M	Buy	50,591 +6,582	+15%	+$756K	0.74%	27
2017 Q1	$6.32M	Buy	44,009 +4,217	+11%	+$603K	1.07%	22
2016 Q4	$5.04M	Buy	39,792 +18,925	+91%	+$2.63M	1.01%	22
2016 Q3	$3.19M	Sell	20,867 -2,053	-9%	-$290K	0.6%	23
2016 Q2	$2.64M	Hold	22,920	–	–	0.56%	27
2016 Q1	$2.6M	Buy	22,920 +171	+0.8%	+$25.9K	0.64%	23
2015 Q4	$4.29M	Buy	22,749 +10,844	+91%	+$2.03M	0.73%	22
2015 Q3	$2.02M	Buy	+11,905	New	+$4.3M	0.41%	23
2015 Q2	–	Sell	-9,014	Closed	-$4.64M	–	34
2015 Q1	$4.64M	Sell	9,014 -5,919	-40%	-$2.99M	0.97%	20
2014 Q4	$8M	Buy	+14,933	New	+$6.73M	1.56%	19

Other funds holding VIRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BVF Inc's VIRX Position: Q3 2024 in Review

BVF Inc sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 3,614,662 shares — an estimated $1.97M sold.

BVF Inc first reported a position in VIRX in Q4 2014 and held it in 38 quarters. The position peaked at $35.1M in Q2 2021. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

BVF Inc reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
BVF Inc sold 3,614,662 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.97M.
BVF Inc first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 38 quarters.
BVF Inc's Viracta Therapeutics, Inc. Common Stock position peaked at $35.1M in Q2 2021.
38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on BVF Inc's 13F filing for Q3 2024, filed 14 Nov 2024.